GET DAILY SIGNALSAtriCure (ATRC): Path to a +12.6% Move Toward the $68 Analyst Target
Key Takeaways
- The central price target of $68 is the arithmetic mean of the six verified analyst price targets currently above the latest closing price of $60.41 for AtriCure (Nasdaq: ATRC).
- The overall average of all valid analyst targets is lower—near $57.56—which is below the current price, so the $68 figure reflects only the targets that sit above the stock's latest close.
- Analyst targets span a wide range from about $36 to $70, signaling genuine disagreement about the company's valuation after a sharp rally.
- Reaching $68 would require roughly a 12.6% advance, a modest move relative to the stock's recent doubling in value.
- The strongest supports are double-digit revenue growth, a fast-growing pain-management franchise, and upcoming clinical catalysts.
- The biggest risks are a stretched valuation, emerging pulsed field ablation competition, and execution risk around pivotal trial data.
- For more on this ticker, explore its Major News, Today's Price Move, Forecast, and Earnings pages.
- Explore Trending AI Robots to see AI-driven trading strategies in action.
Analyst Price Targets and Consensus View
AtriCure, Inc. develops medical devices for surgical treatment of atrial fibrillation, left atrial appendage management, and post-operative pain. After the stock's sharp climb, the broader analyst consensus now sits below the latest close. S&P Global data places the mean target near $57.56, with estimates ranging from roughly $36 to $70. That is why the $68 level used here averages only the verified targets above the current price rather than the full consensus.
Six such targets were examined. BTIG (Marie Thibault), Needham (Mike Matson), and Piper Sandler (Matt O'Brien) each lifted their targets to $70 after the company reported better-than-expected third-quarter results. Citizens JMP set a target at $68, Canaccord at $67, and Stifel at $65. Their average comes to $68.33, which rounds to $68. UBS holds a $50 target and Freedom Capital a $57 target; the latter also downgraded the shares to Hold in October, citing a significant premium to peers.
Current Market Position and Path Toward the Target
With a recent close near $60.41, a move to $68 would represent an advance of about 12.6%. That is modest by historical standards, especially after the shares more than doubled from roughly $28 in late June 2026. The 52-week high sits near $61.71, so the stock is trading just below that mark. Continued momentum in the pain-management business, which grew 27% year over year in the first half of 2026, along with steady gains in open ablation and appendage management, would likely be needed to sustain any push higher. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
What Could Support a Move Toward the Target
Fundamentals have strengthened. Total revenue has risen about 14% over the past year, gross margins are near 76%, and management raised profitability guidance with the latest report. Analysts point to a new Society of Thoracic Surgeons quality measure that favors pre-operative Afib treatment as an underappreciated catalyst for open ablation. Longer term, data from the BoX-NoAF trial for post-operative atrial fibrillation, expected in early 2027, could support label expansion and a larger addressable market.
What Could Prevent the Target From Being Reached
Valuation remains the main concern. The stock trades at a forward P/E above 200 times, offering little room for error if growth slows. Pulsed field ablation competition from larger rivals such as Edwards Lifesciences (EW) and Boston Scientific (BSX) has already led to downgrades. Any shortfall in pain-management momentum, softer guidance, or disappointing BoX-NoAF results could compress the multiple and weigh on the shares.
Technical Levels and Market Structure
The stock is hovering just below its 52-week high near $61.71, which serves as the nearest resistance zone. A decisive break above that level would bring the $65 and $68 analyst targets into view. On the downside, the $55–$57 area, where several lower targets cluster, represents a potential support zone. The sharp run since mid-2026 leaves the shares extended, so pullbacks could develop quickly if sentiment shifts.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a roughly 12-month horizon, though individual firms do not always publish identical timeframes. Key items to watch include quarterly revenue and guidance updates, the trajectory of the pain-management and open ablation segments, analyst target revisions, the BoX-NoAF trial readout expected in early 2027, and any competitive or regulatory developments in the pulsed field ablation market. From what I see, these factors will determine whether the recent rally can extend.
Using AI Daily Buy/Sell Signals for Additional Perspective
In my own research process, I sometimes review Tickeron’s AI Daily Buy/Sell Signals to gain a data-driven view of how market conditions and technical factors are evolving for a given name. The platform applies artificial intelligence to monitor thousands of stocks and ETFs, producing Buy, Sell, or Hold signals that can help identify shifting trends more efficiently than manual screening alone. It serves as one more input when evaluating opportunities like this one.
Final Assessment
The $68 target is a selective figure—the average of the six analyst targets above AtriCure’s current price, not the broader consensus near $57.56. Reaching it would require a modest 12.6% gain, supported by double-digit revenue growth, a fast-growing pain franchise, and upcoming clinical catalysts. At the same time, a forward P/E above 200 times, intensifying pulsed field ablation competition, and the risk of a disappointing BoX-NoAF outcome remain material obstacles. The wide $36-to-$70 target range reflects real disagreement about whether the recent rally has already priced in the company’s growth prospects. Investors should focus on upcoming guidance, competitive updates, and the 2027 trial readout rather than any single price level.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ATRC in -4.16% downward trend, falling for three consecutive days on November 02, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ATRC declined for three days, in 255 of 309 cases, the price declined further within the following month. The odds of a continued downward trend are 83%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for ATRC moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In 23 of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at 77%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 45 of 62 cases where ATRC's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 73%.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on ATRC as a result. In 59 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.
The Moving Average Convergence Divergence (MACD) for ATRC just turned positive on October 23, 2026. Looking at past instances where ATRC's MACD turned positive, the stock continued to rise in 39 of 46 cases over the following month. The odds of a continued upward trend are 85%.
Following a +4.31% 3-day Advance, the price is estimated to grow further. Considering data from situations where ATRC advanced for three days, in 214 of 304 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
ATRC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 147 of 222 cases where ATRC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 66%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. ATRC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 88 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.950) is normal, around the industry mean (4.946). ATRC's P/E Ratio (274.591) is considerably higher than the industry average of (38.797). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (4.869) is also within normal values, averaging (56.876).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ATRC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of surgical and medical instruments
Industry PharmaceuticalsOther
Advertisement